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Abstract
Canavan Disease (CD) is a recessive leukodystrophy caused by loss of function mutations in the gene encoding
aspartoacylase (ASPA), an oligodendrocyte-enriched enzyme that hydrolyses N-acetylaspartate (NAA) to acetate and
aspartate. The neurological phenotypes of different rodent models of CD vary considerably. Here we report on a novel
targeted aspa mouse mutant expressing the bacterial b-Galactosidase (lacZ) gene under the control of the aspa regulatory
elements. X-Gal staining in known ASPA expression domains confirms the integrity of the modified locus in heterozygous
aspa lacZ-knockin (aspa
lacZ/+) mice. In addition, abundant ASPA expression was detected in Schwann cells. Homozygous
(aspa
lacZ/lacZ) mutants are ASPA-deficient, show CD-like histopathology and moderate neurological impairment with
behavioural deficits that are more pronounced in aspa
lacZ/lacZ males than females. Non-invasive ultrahigh field proton
magnetic resonance spectroscopy revealed increased levels of NAA, myo-inositol and taurine in the aspa
lacZ/lacZ brain.
Spongy degeneration was prominent in hippocampus, thalamus, brain stem, and cerebellum, whereas white matter of optic
nerve and corpus callosum was spared. Intracellular vacuolisation in astrocytes coincides with axonal swellings in
cerebellum and brain stem of aspa
lacZ/lacZ mutants indicating that astroglia may act as an osmolyte buffer in the aspa-
deficient CNS. In summary, the aspa
lacZ mouse is an accurate model of CD and an important tool to identify novel aspects of
its complex pathology.
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Introduction
Aspartoacylase (ASPA) deacetylates N-acetyl-aspartate (NAA) to
produce acetate and L-aspartate. This enzyme is a marker of
mature oligodendrocytes [1,2,3] and mutations of the aspa gene
cause the fatal recessive leukodystrophy Canavan disease (CD)
[4,5]. Patients suffer from mental retardation, hypotonia, seizures
and death usually before the age of ten. Pathological changes
include strongly elevated NAA levels in blood and urine,
oligodendrocyte death and a progressive CNS vacuolization [6].
The underlying mechanisms of these multifaceted abnormalities
are not understood and it is not clear to what extent the deficiency
of ASPA in cell types other than oligodendroglia contributes to the
development of clinical signs observed in CD. The monogenic
nature of CD, and the lack of an effective treatment have provided
the rationale for in vivo gene transfer into the CNS of patients and
ASPA-deficient animals [7]. While these animal models generally
reprise the pathological hallmarks observed in CD, they show
substantial differences in disease severity and longevity [8,9,10].
The vast majority of clinical cases can be assigned to the relatively
moderate infantile form of CD suggesting that an accurate animal
model is expected to display a mild disease severity. Moreover, the
identification of all ASPA expression domains is essential to gain a
comprehensive picture of the complex CD pathology and design
effective therapies.
Here, we describe an engineered mouse line expressing the
bacterial lacZ gene under the control of the aspa promoter.
Homozygous lacZ-knockin (aspa
lacZ/lacZ) mutants are ASPA-
deficient and show distinct abnormalities reminiscent of CD.
Results
Disruption of ASPA expression in aspa-lacZ knockin mice
Based on a knockout-first strategy that produces a knockout at
the RNA processing level [11], targeting of the aspa locus in
C57bl/6 ES cell was achieved by inserting the bgeo cassette
(including the genes encoding b-Galactosidase and Neomycin)
flanked by frt sites into intron 1 of the intact aspa gene.
Additionally, exon 2 was flanked by loxP sites for optional
conditional deletion of the targeted locus (Fig. 1A). The successful
selection process after transfection of the targeting vector requires
activity of the aspa gene locus in ES cells suggesting aspa expression
at very early stages during development. Two clones with
homologous recombination events were injected into blastocysts
and germ line transmission confirmed after appropriate matings.
Heterozygous aspa
lacZ/+ males and females were crossed to obtain
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+/+, aspa
lacZ/+ and aspa
lacZ/lacZ littermates at the expected
Mendelian ratios (24.9%, n=59; 51.9%, n=123; 23.2%, n=55)
for the three genotypes. A single targeting event was confirmed by
Southern blot analysis of genomic DNA obtained from liver of all
three genotypes using a neomycin probe (Fig. 1B). The modified
aspa locus could also be identified by PCR producing amplicons of
the expected sizes (Fig. 1C). The bgeo cassette was flanked by an
upstream 3’ splice acceptor site and a downstream transcriptional
termination sequence resulting in an exon1-bgeo fusion transcript.
The corresponding fusion protein contains the N-terminal 77
amino acid residues of ASPA with no predicted enzymatic activity
[12]. Because inactivation of the aspa gene was designed to
attenuate transcription upstream of exon 2, we determined aspa
mRNA levels in the brain of aspa
+/+, aspa
lacZ/+ and aspa
lacZ/lacZ
mice (n=3) by quantitative real-time (Q-RT) PCR. Using a
TaqMan probe binding to a downstream sequence, aspa mRNA
levels were undetectable in aspa
lacZ/lacZ mice, while we observed a
60.464.3% (p=0.0001) reduction of mRNA expression in
aspa
lacZ/+ brains compared to controls (Fig. 1D). We then used a
rabbit anti-ASPA antibody to determine the ASPA protein levels
in immunoblot analysis of whole brain homogenates of 2 months
old aspa
+/+, aspa
lacZ/+ and aspa
lacZ/lacZ mice (n=3). In the presence
of one functional allele in heterozygous aspa
lacZ/+ animals, ASPA
was reduced to 74.565.7% (p=0.048) of control levels and was
completely abolished in homozygous aspa
lacZ/lacZ mutants (Fig. 1E).
Analysis of b-Galactosidase levels showed the complementary
profile with moderate levels in aspa
lacZ/+ mice and increased levels
in aspa
lacZ/lacZ mutants reflecting gene dosage effects. Phenotypi-
cally, aspa
lacZ/lacZ mutants were smaller (Fig. 1F) and showed gait
abnormalities starting before weaning. The body weight of
aspa
lacZ/lacZ mice was significantly decreased at P40 compared
with controls for both sexes (aspa
+/+ 19.0560.83 g vs. aspa
lacZ/lacZ
14.7060.67 g males, p,0.001; aspa
+/+ 16.8460.30 g vs. aspa
lacZ/lacZ
13.9360.58 g females, p,0.001). Using flp-deleter mice, the
aspa
lacZ/lacZ allele could be converted via excision of the bgeo
cassette to the floxed aspa
f/f allele (Fig. 1A). The latter is
phenotypically identical to the wildtype allele and will be
instrumental for conditional deletion of the aspa gene via Cre-
mediated recombination (our unpublished observations).
ASPA expression domains
The genomic configuration of the modified locus was designed
to recapitulate the activity of the aspa promoter and analysis of
aspa
lacZ/+ heterozygots by X-Gal immunohistochemistry detected
the presence of the soluble enzyme b-Galactosidase in central and
peripheral tissues (Fig. 2 A–G). X-Gal was detected in oligoden-
drocytes throughout the brain. Intense staining was observed in
corpus callosum, but was also present in subcortical grey matter
(Fig. 2A). Fibre tracts in the thalamus showed strong X-Gal
staining indicating the presence of b-Galactosidase in oligoden-
drocyte processes (Fig. 2B). Brain stem and cerebellar white matter
also displayed abundant X-Gal signals (Fig. 2C). At higher
magnification, X-gal signal was visualized in the soma and
proximal processes of oligodendrocyte in the cerebellum (Fig. 2D).
We also investigated the activity of the aspa promoter in the
periphery and observed abundant X-Gal staining in small intestine
and kidney (Fig. 2E,F) confirming previous reports on ASPA
expression in these organs [7,13,14]. X-Gal staining in the kidney
was found in proximal tubules, but was absent from medulla and
glomeruli. This expression pattern matches the distribution of
ASPA immunoreactivity in this organ [14]. We also observed X-
Gal staining in fibres of the sciatic nerve (Fig. 2G). However, the
histological approach did not resolve whether b-Galactosidase was
localized to Schwann cells or the underlying axons. No unspecific
staining was observed in identically processed tissues from aspa
+/+
controls (not shown).
We then determined ASPA immunoreactivity specifically in
oligodendroctyes of homozygous Plp-DsRed-1 transgenic mice
expressing the RFP reporter protein under the control of the plp-1
promoter [15]. On the subcellular level, staining was detected in
soma and proximal processes of oligodendrocytes (Fig. 2H–J)
confirming previous findings by us and others [2,3]. Double
immunohistochemical detection revealed that immunoreactivities
of both b-Galactosidase and ASPA exactly co-localized in the
brain of heterozygous aspa
lacZ/+ mice further validating this
reporter line as a genetic tool to monitor the activity of the aspa
gene (Supporting Information Figure S1).
To discern ASPA expression in the sciatic nerve, we performed
confocal analysis of ASPA immunoreactivity with teased nerve
fibres of aspa
+/+ mice (Fig. 2K–M). ASPA was detected in
protoplasmic domains of Schwann cells and segregated from the
myelin marker MBP. Our results show that ASPA is present in
myelinating glia of the central and peripheral nervous system.
Since the histological approach precludes quantitative analyses we
conducted Q-PCR to determine the relative abundances of aspa
mRNA in different organs obtained from adult aspa
+/+ animals.
Expression levels in kidney, spinal cord, small intestine, and sciatic
nerve were almost two-fold more than that in brain (Fig. 2N).
Since peripheral neurons were devoid of ASPA immunoreactivity
(Fig. 2K–M), our PCR data suggest that Schwann cells are the
main source of aspa mRNA in the sciatic nerve. Moderate levels of
expression were detected in muscle, testis and lung, and negligible
in whole body preparation at embryonic day E13.5 and E16.5.
CD-like histopathology in aspa
lacZ/lacZ mutants
Histological analysis of Nissl stained brain sections of aspa
lacZ/lacZ
mutants (4 months old) revealed spongy degeneration throughout
the CNS. Vacuolisation was prominent in hippocampus, thala-
mus, brainstem, cerebellum, and spinal cord. In contrast, the white
matter tracts of corpus callosum and optic nerve were remarkably
intact (Supporting Information Figure S2). In the hippocampus,
vacuoles occurred specifically in the pyramidal cell layer while
dentate granule cells were spared (Fig. 3A and B). In contrast, the
thalamus was uniformly affected (Fig. 3C and D). Spongy
degeneration was abundant in the dorsal region of the brain stem
(Fig. 4A, B, G, H). EM analysis revealed swollen and degenerated
axons in the presence of normal myelin in the ventral aspect of the
brain stem (Fig. 4C, D). In the dorsal brain stem hypomyelination
and axonal swellings were observed (Fig. 4E, F). In the cerebellum,
vacuolisation was detected in white matter, the granule cell layer
and the Purkinje cell layer but not in the molecular layer (Fig 4I, J,
K, L). At the ultrastructural level, swollen Bergman glia showed
accumulations of electron dense particles (Fig. 4N, P). The nature
of the latter could not be determined. Interestingly, the parallel
fibre to Purkinje cell dendrite synapses appeared normal (Fig. 4M,
N).
Regulation of myelin associated proteins
Levels of myelin proteins were investigated by immunoblot
analysis of whole brain lysates of aspa
+/+, aspa
lacZ/+ and aspa
lacZ/lacZ
littermates (at 2 months; n=3 per group). In homozygous
mutants, the major CNS myelin protein PLP and its smaller
isoform, DM20, were reduced to 45.961.4% (p=0.001) and
8.762.7% (p=0.004), respectively (Fig. 5). The reason for the
relatively stronger regulation of DM20 is unclear. The 21.5 kD
and 18.5/17 kD MBP isoforms were reduced to 32.960.9%
(p,0.001) and 65.763.8% (p=0.002), respectively. CNP was only
moderately downregulated to 72.064.8% (p=0.011). Heterozy-
Aspartoacylase-LacZ Knockin
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lacZ/+ mice did not differ from aspa
+/+ controls. These
results further suggest that demyelination is present in aspa
lacZ/lacZ
mutants.
Reactive gliosis in aspa
lacZ/lacZ mutants
Increased numbers of astrocytes and microglia have been
reported in CD [16]. Therefore, we performed immunohisto-
chemical analyses using brain sections of controls and mutants
characterized by the presence (aspa
+/+) or absence (aspa
lacZ/lacZ)o f
ASPA immunoreactivity (Fig. 6). Microglia activation in the
mutant thalamus was detected by Iba-1 immunohistochemistry
(Fig. 6). Assessment of glial acidic fibrillary protein (GFAP)
immunoreactivity revealed increased astrocyte numbers in the
thalamus of aspa
lacZ/lacZ mice. Astrogliosis was less prominent in
white matter tracts where vacuolisation did not occur, such as
corpus callosum (not shown).
Metabolic imbalances in aspa
lacZ/lacZ mutants
The lack of ASPA leads to accumulation of its substrate NAA in
brains of patients and CD models [7,10]. Ultrahigh field proton
magnetic resonance spectroscopy (
1H MRS) at 9.4T allows non-
invasive quantification of metabolites, like NAA, glutamate,
glutamine, GABA, taurine, and glucose in the living rodent brain
(Fig. 7). We focused on the thalamus and prefrontal cortex because
these regions showed high and low degree of vacuolization,
respectively. We found substantially more of NAA (255.8%), myo-
inositol (330.6%), taurin (204.4%) and glutamin (122.0%) in the
aspa
lacZ/lacZ thalamus compared to the control, while glutamate was
Figure 1. Generation of aspa
lacZ mice by homologous recombination. A, Genomic structure of the murine aspa locus, which spans 6 exons
(black boxes). Homologous recombination of the targeting vector inserts the bgeo cassette (blue box), encoding b-Galactosidase (lacZ), into intron 1
of the intact aspa gene. This cassette is flanked by frt-sites (green circles). Additional loxP sites flank exon 2 (red triangles). The vector includes a DTA
cassette for negative selection. In the targeted allele, exon 1 is spliced to the splice acceptor site preceding bgeo, and transcription is terminated at
the introduced pA site. The conditional aspa
flox allele is produced by breeding aspa
lacZ mutants to FLP-deleter mice [40] for recombination of the
bgeo cassette in vivo. Note that frt and loxP sites are not drawn to scale. bgeo, b-galactosidase-neomycin resistance cassette; SA, splice acceptor; pA,
polyadenylation site, DTA, Diphteria toxin gene. B, For Southern blot analysis genomic DNA was digested with SmaI/ApaI. The neo probe (white box
in A) detected the expected 7.5 kb band in heterozygotes and homozygotes. C, Genomic PCR of littermates with primers 1 & 3 produces the
expected amplicons in aspa
+/+ (336 bp), aspa
lacZ/+ (387 bp and 336 bp) and aspa
lacZ/lacZ (387 bp) animals. The upstream loxP site was detected by
PCR with primers 1 & 2 yielding a 307 bp band. D, Q-RT-PCR using a TaqMan probe for quantification of aspa mRNA levels in brains of aspa
+/+,
aspa
lacZ/+, and aspa
lacZ/lacZ mice (n=3) confirms the attenuation of transcription downstream of exon 2 in the targeted allele. E, Representative
Western blot of whole brain lysates of aspa
+/+, aspa
lacZ/+ and aspa
lacZ/lacZ mice (aged 4 months, n=3). The 37 kD protein ASPA was detected in aspa
+/+
and aspa
lacZ/+ mice but not in aspa
lacZ/lacZ mutants. b-Galactosidase is expressed in aspa
lacZ/+ and aspa
lacZ/lacZ brain but not controls. a-Tubulin was used
as loading control. F. Representative picture of a male aspa
lacZ/lacZ mutant (asterisk) and an aspa
+/+ littermate at P70.
doi:10.1371/journal.pone.0020336.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20336Figure 2. Analysis of aspa expression in CNS and periphery. A–D, Representative pictures of b-Galactosidase staining in adult aspa
lacZ/+
mouse tissues show activity of the aspa gene in oligodendrocytes of white and grey matter throughout the brain. Abundant staining was detected in
white matter tracts in cerebellum and corpus callosum. While in the hippocampus and cortex X-Gal staining was found in oligodendrocyte cell bodies
(A), lacZ-positive fibres were detected in the thalamus (B). In the cerebellum, proximal processes and somata of white matter oligodendrocytes were
stained (C, D). E–F, Outside the CNS, the cortex of the kidney (E), small intestine (F) and sciatic nerve fibres (G) show intense X-Gal staining. H–J,
Confocal detection of ASPA immunoreactivity (H) in cerebellar white matter of an adult Plp-DsRed-1 transgenic mouse expressing the red fluorescent
Aspartoacylase-LacZ Knockin
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limitations in resolution, the N-acetylaspartylglutamate (NAAG)
peak could not be discerned from the NAA signal. While in the
prefrontal cortex there was an increase in NAA (75.5%), myo-
inositole (75.4%) and taurine (22.4%), these changes were not as
prominent as in the thalamus. Of note, the reduction in GABA
(26.4%) was similar to that seen in thalamus while creatine was
virtually unchanged in both areas.
Interstitial NAA levels can also increase via the hydrolysis of
NAAG by the astrocyte-specific plasma membrane enzyme folh1/
glutamate carboxypeptidase II (EC 3.4.17.21). Therefore we
investigated the mRNA expression levels of this enzyme and found
no changes in aspa
lacZ/+ (103.966.9%; p=0.652) but a reduction
of 48.163.6% (p,0.0001) in aspa
lacZ/lacZ mice (Supporting
Information Figure S3). This decrease was not due to a reduction
in astrocyte numbers (Fig. 6) and might represent a cellular
mechanism to prevent additional generation of NAA from NAAG
in an environment of pathologically enriched NAA.
Sexual dimorphism in behavioural outputs of aspa
lacZ/lacZ
mice
CD is characterized by general muscle weakness and the failure
to develop motor control. We observed ataxia with splayed hind
legs and a general lack of muscle tonus in male and female mutants
but not their respective littermate controls starting at the age of 3–
4 weeks. These gait abnormalities progressed gradually to obvious
deficits in motor coordination, and weakness especially in the hind
limbs. Supporting Video S1 shows representative behaviour of
male mutant and control mice at 2 months of age. At the time of
this report, all aspa
lacZ/lacZ mutants had survived .1.5 years
suggesting normal longevity. However, they showed progressive
immobility and impaired motor function characterized by
spasticity and jerky movements. When we started to monitor
motor learning and general locomotion in specialised behavioural
tests, we used aged-matched (P90) cohorts of mutant and wt mice
that included pools of both sexes, and obtained inconsistent data.
We then analysed male aspa
lacZ/lacZ and aspa
+/+ littermates
separately from the female cohorts. To quantify behavioural
deficits in younger animals, we assessed their motor coordination
using the rotarod test. At P90, we observed significant differences
within both male (aspa
+/+ 203.3626.2 s vs. aspa
lacZ/lacZ
100.2611.0 s; p=0.0012; two-tailed t-test) and female (aspa
+/+
210.5621.2 s vs. aspa
lacZ/lacZ 120.9611.2 s; p=0.0046) cohorts
(Fig. 8A). We also investigated the inherent locomotor and
exploratory activity of both cohorts in an open field (Fig. 8B). We
found that motor activity monitored by the total distance travelled
over a 30 min period, was reduced in male (aspa
+/+
reporter protein (I) in oligodendrocytes [15]. ASPA is expressed in somata and processes of oligodendrocytes. The pattern of ASPA-immunopositive
cells matches the DsRed-expressing oligodendrocytes (J). K–M, Confocal detection of ASPA immunoreactivity in cytosolic domains of wildtype
Schwann cells. ASPA is enriched at the paranode (asterisk) and bands of Cajal (arrow heads) and segregates from MBP. N, Q-PCR analysis of aspa
mRNA levels in different tissues of adult aspa
+/+ mice (n=6). hc, hippocampus; ctx, cortex; med, medulla; tha, thalamus; wm, white matter. Bars:
500 mm in A,C,E; 200 mm in B, D; 400 mm in F,G; 20 mm in H–J; 10 mm in K–M.
doi:10.1371/journal.pone.0020336.g002
Figure 3. CNS vacuolisation in aspa
lacZ/lacZ mutants. Representative pictures of Nissl stained brain sections of aspa
+/+ (A,C) and aspa
lacZ/lacZ (B,D)
mice (4 months). Vacuoles are abundant in forebrain grey matter of cortex and thalamus while white matter of the corpus callosum is spared (B). In
the hippocampus, the histopathology is exclusively seen in the pyramidal but not the dentate granule cell layer. Magnifications of thalamic areas
show substantial spongy degeneration in the mutant (arrows in D) but not in the control (C). hc, hippocampus; cc, corpus callosum; ctx, cortex; dcl,
granule cell layer; pcl, pyramidal cell layer; tha, thalamus. Bars: 400 mm in A,B; 200 mm in C,D.
doi:10.1371/journal.pone.0020336.g003
Aspartoacylase-LacZ Knockin
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lacZ/lacZ 75476439.2 s; p=0.0042; two-
tailed t-test) but not in female mutants compared with sex-
matched controls (aspa
+/+ 88386340.9 s vs. aspa
lacZ/lacZ
95276955.0 s; p=0.4849; two-tailed t-test). Male mutants spent
more time in the centre of the test arena than controls (aspa
+/+
232.6625.3 s vs. aspa
lacZ/lacZ 411.2640.1 s; p=0.0071; two-tailed
t-test) and only slightly less time in the periphery (aspa
+/+
1567625.3 s vs. aspa
lacZ/lacZ 1389640.1 s; p=0.0021; two-tailed
t-test), suggesting reduced anxiety-like behaviour. In contrast,
there was no difference within the female cohort (Center: aspa
+/+
Figure 4. Histopathology of the brain stem and cerebellum in aspa
lacZ/lacZ mice. Caudal brain stem of controls (A, C, F, G) and aspa
lacZ/lacZ
mice (B, D, E, H): Vacuolization is abundant in the dorsal region aspa
lacZ/lacZ mice (solitary tract nu, commissural, SolC) as shown in semithin sections
(B) and electron microscopy (H). In the pyramidal tract of mutant mice myelin appears normal, but axonal swellings and degeneration are present (D,
asterisks). Axonal swellings as well as hypomyelination were found in the dorsal region with abundant vacuolization (F, asterisk). Cerebellum of
controls (I, K, M, O) and aspa
lacZ/lacZ mice (J, L, N, P): In semithin sections of mutant cerebellum, vacuoles are detectable in the white matter (WM),
granule cell layer (GL) and in the Purkinje cell layer (J, L). Parallel fibre to Purkinje cell dendrite synapses appear normal (M, N), but in aspa
lacZ/lacZ
mice the Bergman glia (BG) is swollen and shows accumulation of electron dense particles (N, P). BG, Bergman glia; CC, central canal; GL, granule cell
layer; ML, molecular layer; PC, Purkinje cell; PF, parallel fibre; SolC, solitary tract nu, commissural; WM, white matter. Scale bars: 100 mm( A, B, I, J),
5 mm( K, L), 2 mm( G, H), 1 mm( C, D, O, P), 500 nm (M, N).
doi:10.1371/journal.pone.0020336.g004
Aspartoacylase-LacZ Knockin
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20336246.5644.0 s vs. aspa
lacZ/lacZ 295.2655.2 s; p=0.4989; Periphery:
aspa
+/+ 1554644.0 s vs. aspa
lacZ/lacZ 1505655.2 s; p=0.4989; two-
tailed t-test).
Discussion
We describe a novel ASPA-deficient mouse mutant obtained by
a targeted insertion of the bgeo cassette in-frame with exon 1 of
the aspa gene. The gene trap approach allowed to re-capitulate the
activity of the endogenous aspa promoter by expression of the lacZ
reporter in central and peripheral tissues. In fact, we found that in
wildtype mice, aspa mRNA quantities in kidney, small intestine
and sciatic nerve were higher than in brain indicating a role for
NAA deacetylation in peripheral tissues. The loss of ASPA in the
periphery appears to be well-tolerated in humans because the
pathology in CD is restricted to the brain [6]. The failure to
degrade NAA and/or other unknown substrates in ASPA
expressing peripheral organs might have indirect toxic conse-
quences for the CNS without inducing major histological
abnormalities in the periphery. While a previous study employed
in situ hybridization and reported on the lack of aspa mRNA
signals in sciatic nerve [17], we provide strong evidence for the
presence of high levels of aspa mRNA in Schwann cells. NAA was
reported in sciatic nerve and ASPA-dependent deacetylation
might contribute to lipid synthesis during PNS myelination similar
to the function of ASPA in oligodendrocytes [18,19]. This raises
the possibility that ASPA-deficiency might have detrimental effects
for peripheral nerve integrity. However, aspa
lacZ/lacZ sciatic nerve
tissue showed no gross abnormalities (our unpublished results)
confirming a report on the normal PNS of the spontaneous ASPA-
null tremor rat [20]. Of the few reports on peripheral nerve tissue
of CD patients, only one case showed axonopathy and
demyelination, but no vacuolisation [21], suggesting that this
unique peripheral lesion might represent a coincidence rather than
a consequence of ASPA-deficiency. How can the remarkably
abundant expression of ASPA in normal Schwann cells be
reconciled with the grossly normal peripheral nerves of ASPA-
deficient mice? The physiology of peripheral nerve fibres differs
from those in the CNS and Schwann cells might be more resistant
to the effects of ASPA-deficiency (i.e. decreased pools of acetate,
NAA toxicity) than oligodendrocytes. Alternatively, there might be
subtle functional abnormalities in the ASPA-null PNS that are yet
to be identified.
Ultrahigh field proton magnetic resonance spectroscopy re-
vealed a substantial increase in levels of NAA but also taurine and
myo-inositol in thalamus, and to a lesser extent in prefrontal cortex
of aspa
lacZ/lacZ mutants. Increased taurine in the aspa
lacZ/lacZ brain
may contribute to preservation of neuronal function via GABAA-
mediated hyperpolarisation of thalamic relay neurons [22]. The
profound increase of NAA in the CD brain is unique among
neurological conditions and NAA-toxicity had been proposed as a
reason for neuronal dysfunction [23,24]. The efflux of NAA from
neurons to the extracellular space is accompanied by a co-
transport of water molecules, causing the interstitial pressure to
Figure 5. Myelin protein levels are reduced in aspa
lacZ/lacZ mutants. Western blot analysis of PLP, DM20, CNP and MBP levels in whole brain
lysates of aspa
+/+, aspa
lacZ/+ and aspa
lacZ/lacZ mice (P60, n=3). Quantification of immunoblots shows statistically significant decreases of all proteins
tested in homozygous mutants while the presence of one functional aspa allele is sufficient to preserve protein quantities at control levels. Note: PLP,
DM20, and the MBP21.5 kD and MBP18.5/17 kD isoforms were analysed separately.
doi:10.1371/journal.pone.0020336.g005
Aspartoacylase-LacZ Knockin
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precursor to phosphatidylinositol, a major membrane phospho-
lipid. Extracellular tonicity induces the transport of myo-inositol
from the outside to the inside of neurons and astrocytes [26]. In
the ASPA-deficient brain, the dramatic increase in astrocyte
numbers and concomitant increase in interstitial pressure may lead
to glial uptake of myo-inositol to prevent cytotoxic damage to
hypertonic neurons. The contribution of myo-inositol to the
metabolic pathology in CD patients might have been underesti-
mated since studies using in vivo imaging of CD brains detected no
or only a moderate increase in prefrontal cortex or cerebellar
white matter, respectively [27,28]. These human data did not
provide information on the thalamus. Our results also showed only
a slight increase in prefrontal cortex myo-inositol. However, the
changes in thalamus were severe, indicating that more dramatic
metabolic changes might occur in the thalamus of the CD brain.
Although the NAAG signal was not determined, down-
regulation of the NAAG-degrading enzyme folh1 in mutants
indicates that levels of this metabolite may be increased. NAAG is
neuroprotective in a number of neurological diseases by inhibiting
the release of glutamate and GABA after activation of presynaptic
mGluR3 [29]. In fact, we found both neurotransmitters to be
decreased in the aspa
lacZ/lacZ brain indicating that this neuropro-
tective mechanism might be impaired. ASPA is not expressed in
astrocytes, yet this cell type appears to be particularly vulnerable
for the osmotic downstream effects of accumulated NAA because
astroglia are integral for the metabolism of NAAG, NAA and
myo-inositol.
Swellings and vacuolisation appear within astrocytes before they
become more prominent in the interstitium of CD patients [16].
These abnormalities precede widespread neuronal damage and
neurological deterioration suggesting that astroglia may buffer
some of the excess metabolites to compensate extracellular
tonicity, sustain axonal integrity and promote neuronal survival.
Bergmann glia contained osmiophilic inclusions reminiscent of
accumulations of glycogen granules. The identity of these electron-
dense particles could not be determined and might represent
advanced stages of intracellular digestion of phagocytosed
material, or signs of direct damage to the Bergmann glia fibres.
Damaged CNS neurons have been reported in CD, the Nur7
mutant, the tremor rat and the aspa
lacZ mouse [10,30,31],
suggesting that changes in axon integrity and metabolic status of
the neuron contribute to the complex pathology. ASPA expression
has been detected in wildtype neurons [3], and one could speculate
that ASPA-mediated degradation of NAA might become impor-
tant in energetically challenged neurons [32]. This concept is
supported by reports on increased aspa gene activity in peripheral
tissues in non-CNS diseases and is yet to be shown to occur in
neurons [13,33]. The distinct anatomical regions where spongy
degeneration and hypomyelination occurred might be accounted
for by the fact that different types of oligodendrocytes show
regional variation in their connectivity to astrocytes via gap
junctions, an important factor in regulating osmotic and metabolic
homeostasis [34].
Congenital, infantile and juvenile forms of CD showing variable
disease onset and severity have been suggested, with the moderate
Figure 6. Reactive gliosis in aspa
lacZ/lacZ mice. Immunohistochemical staining in the thalamus of aspa
+/+ controls and aspa
lacZ/lacZ mice showed
substantially increased numbers of GFAP-positive astrocytes and Iba-1-positive microglia in the mutants (at 3 months of age). Note that ASPA
immunoreactivity is present in the control but not in the mutant. Bars: 25 mm.
doi:10.1371/journal.pone.0020336.g006
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pathology observed in aspa
lacZ/lacZ mutants includes region specific
spongy vacuolisation of the CNS, elevated NAA levels, demyelin-
ation, gliosis, and impaired motor behavior. As such, this mouse
line is an accurate model of infantile CD. The aspa
lacZ/lacZ line has
been derived from C57BL/6J ES cells and shows a considerably
milder phenotype compared with the previously described Aspa-
KO mouse [9]. The latter line was obtained after the targeted
Figure 7.
1H-MRS analysis. Spectra were acquired from aspa
+/+ and aspa
lacZ/lacZ littermates using a 26263m m
3 single-voxel PRESS Sequence in
the thalamus. Representativ metabolites are marked in the spectra (Cr: Creatine and Phosphocreatine, NAA: NAA+NAAG, Cho: Phosphocholine and
Glycerophosphorylcholine, Glu: Glutamate, Gln: Glutamine, mI: Myo-Inositol, Tau: Taurine, Glx: Glu+Gln). For metabolite concentrations see Table 1.
doi:10.1371/journal.pone.0020336.g007
Table 1. Metabolite concentrations in the in vivo mouse brain measured with
1H-MRS over a 2*2*3 mm
3 and 3*1.2*2.8 mm
3
volume of interest in the thalamic region and the prefrontal cortex, respectively.
Thalamus Prefrontal Cortex
Control mouse
[mM/l] ± %SD
Aspa-LacZ
[mM/l] ± %SD
Change
%
Control mouse
[mM/l] ± %SD
Aspa-LacZ
[mM/l] ± %SD
Change
%
GABA 3.84 6 4 2.63 6 10 231.4% 2.65 6 7 1.95 6 22 226.4%
Glc 6.19 6 6 4.63 6 12 225.2% 7.19 6 5N / A 6 N/A N/A
Tau 5.50 6 31 6 . 7 5 6 2 204.4% 11.53 6 2 14.12 6 3 22.4%
Gln 3.65 6 4 8.12 6 3 122.2% 2.36 6 6 2.38 6 14 0.7%
Glu 9.28 6 2 3.06 6 9 267.0% 11.21 6 2 8.25 6 5 226.4%
mI 8.06 6 23 4 . 7 0 6 1 330.6% 6.59 6 3 11.56 6 5 75.4%
Lac 5.08 6 4 2.55 6 12 249.9% 3.90 6 6 3.48 6 16 210.9%
Ch 2.58 6 2 1.30 6 4 249.5% 2.35 6 2 2.59 6 5 10.4%
NAA 11.56 6 24 1 . 1 3 6 1 255.8% 11.21 6 2 19.68 6 3 75.5%
Cr 9.66 6 11 0 . 7 5 6 2 11.4% 9.50 6 2 9.50 6 4 0.0%
The standard deviation of the metabolite concentrations (SD) corresponds to the Crame ´r-Rao lower bounds of the LCModel-fit and is given in %. SD-values below 20%
are considered reliable. Error bars are derived through the fit-routine and indicate the quality of individual metabolite measurements. Cr: Creatine and Phosphocreatine,
NAA: NAA+NAAG, Cho: Phosphocholine and Glycerophosphorylcholine, Glu: Glutamate, Gln: Glutamine, mI: Myo-Inositol, Tau: Taurine, Glc: Glucose.
doi:10.1371/journal.pone.0020336.t001
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seizures and premature death occurring as early as at two months
of age. It is tempting to speculate that the genetic background can
modify disease severity. Another major difference between the two
lines is that the aspa
lacZ allele was targeted with a promoterless
selection marker while in Aspa-KO mice the neo gene is driven by
the strong pgk promoter that has been suggested to interfere with
the activity of genes adjacent to aspa [10,36]. Consequently, the
severe phenotype of the Aspa-KO mouse was suggested to be
caused by multiple gene effects [10] that might also account for
subtle differences i.e. unchanged folh1 activity in Aspa-KO mice
[37] versus 50% folh1 mRNA reduction in aspa
lacZ/lacZ mice (this
study). Interestingly, homozygous aspa
Nur7 transgenic mice, carrying
an aspa nonsense mutation identified in an ENU mutagenesis screen
[10], show virtually the same mild neurological and histological
abnormalities as the targeted aspa
lacZ/lacZ line. Additional ENU-
induced mutations in other genes of the Nur7 mutant cannot be
excluded, but both aspa
lacZ and Nur7 mutants are on the C57BL/6J
background eliminating genetic strain differences. In summary, the
aspa
lacZ mouseisuniquebecause the underlying geneticmodification
Figure 8. Special behavioural deficits in male but not female aspa
lacZ/lacZ mutants. A. Analysis of motor coordination in the rotarod test
shows impairment of both female and male aspa
lacZ/lacZ mice compared with their aspa
+/+ controls at P90. B. Spontaneous exploratory activity and
aspects of anxiety-related behaviour of both sexes and genotypes were tested in an open field for 30 min (see Methods section). Male mutants (n=8)
travelled less and spent more time in the centre than male controls (n=8). This behaviour is suggestive of impaired exploratory activity and
anxiolysis. The behaviour of female mutants (n=6) did not differ from female controls (n=7).
doi:10.1371/journal.pone.0020336.g008
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genes, and allows for screening of aspa gene activity.
Behavioural phenotyping of aspa
lacZ mutants revealed sex-
specific consequences of ASPA-deficiency. Rotarod performances
were equally impaired in female and male mutants while different
aspects of locomotor behaviour and inherent anxiety as monitored
in the open field arena revealed sexual dimorphisms. There are no
reports on gender-specific differences in behavioural test perfor-
mance for the ASPA-KO or Nur7 mouse lines. However, a recent
study using the natural ASPA-null tremor rat [8] showed that
locomotor activity is less impaired in female tremor rats than males
[38]. What mechanisms could account for these observations?
Sexual dimorphism of oligodendrocytes in rodents and humans
has been described and there is evidence for androgens to control
oligodendrocyte differentiation and survival by signaling through
their receptors expressed by oligodendroglia (reviewed in [39]).
Therefore, the vulnerability of ASPA-deficient oligodenroglia may
be different between female and male aspa
lacZ/lacZ mutants and this
could translate into differences at the behavioural level.
In summary, aspa
lacZ/lacZ mice represent the accurate model of
Canavan disease, and this line, as well as conditional aspa
f/f
mutants derived from this line, will be essential research tools to
genetically dissect the mechanisms underlying CD and to design
and test effective treatment strategies.
Materials and Methods
Ethics statement
Experiments were approved by the local animal care committee
(Landesuntersuchungsamt Koblenz, permit number 23177/G10-
1-036).
Generation of aspa
lacZ mutant mice
Using homologous recombination in C57bl/6 embryonic stem
(ES) cells, the bgeo cassette (including the genes encoding b-
Galactosidase and Neomycin) was introduced into intron 1 of the
aspa gene by the European Mouse Mutagenesis Consortium
(EUCOMM). In addition, the critical exon 2 was flanked by loxP
sites. An automated high-throughput approach and genotyping by
long-range PCR (for technical see http://www.eucomm.org/) led
to the identification of two independent aspa-lacZ C57bl/6 ES cell
clones (H09 and C09) showing homologous targeting. We injected
both clones into balb/c blastocysts and chimeric males were bred
to C57Bl/6J females to produce germ line transmission. The C09-
derived line was used for further experiments. We intercrossed
heterozygous (aspa
lacZ/+) offspring to obtain homozygous mutant
mice (aspa
lacZ/lacZ) and correct targeting was confirmed by
Southern blot analysis. DNA was digested with ApaI and SmaI
(NEB, Ipswich, MA), separated on a 0.7% agarose gel, blotted
onto Hybond N+ membrane (GE Healthcare, Dassel, Germany)
and probed with a 600 bp
32P-labelled fragment of the Neo-
cassette. Mice were genotyped by PCR using Primer 1 as forward
primer and Primer 3 as reversed primer resulting in a 336 bp band
for the wild-type allele and a 387 bp band for the synthetic allele.
Presence of the loxP site was detected by PCR with Primer 1 as
forward primer and Primer 2 as reversed primer yielding a 307 bp
band. Primer sequences are available upon request. aspa
f/f mice
were generated via flp-mediated recombination and deletion of the
ßgeo cassette after crossing aspa
lacZ/+ animals with flp-deleter mice
[40].
RNA isolation and Q-PCR
Animals were sacrificed at postnatal day P60, organs dissected
quickly, and snap frozen. Brains were homogenized under liquid
nitrogen using mortar and pestle. Total RNA was isolated using the
Nucleo-Spin RNAII-Kit (Macherey-Nagel, Dueren, Germany).
450 ng of DNase-treated total RNA was reverse-transcribed using
High Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Carlsbad, CA). The cDNA equivalent to 22.5 ng RNA was
amplified using commercial TaqMan assays (Applied Biosystems,
Carlsbad, CA) for mouse aspartoacylase (aspa; Mm00480867_m1),
glucoronidase b (gusb; Mm00446953_m1) and folate hydrolase
(folh1; Mm00489655_m1) with an ABI 7300 real time PCR cycler
(Applied Biosystems, Carlsbad, CA). Quantitative RT-PCR reac-
tions were performed in triplicates. Data analysis was done using a
relative expression software tool (REST) using gusb as the reference
gene [41].
Antibody generation
Expression of recombinant human aspartoacylase fused to a C-
terminal 6xHis tag using the bacterial expression vector pET-3a
(New England Biolabs, Beverly, MA) was expressed in E. Coli
(BL21) as described [2]. After induction with IPTG (1 mM) for 4 h,
bacteria were sonicated in a solubilization buffer containing
20 mM Na-phosphate (pH 7.4), 0.5 M NaCl, 5 mM imidazole.
Sonicated bacteria were pelleted, insoluble (pellet) and soluble
(supernatant) fractions were separated by PAGE and ASPA
content analyzed by coomassie staining. Less than 5% of total
ASPA protein was located in the supernatant. Recombinant
soluble ASPA was purifed by affinity chromatography using Ni-
charged agarose (Ni-NTA Agarose, Quiagen, Hilden, Germany).
On the day of injection, purified ASPA (0.1 mg) was mixed with
Freund’s adjuvant and administered i.p. to a rabbit. Every two
weeks the dose was repeated over a total of 12 weeks. Finally, the
animal was sacrificed, blood collected and the serum isolated.
Histology
For immunohistochemistry mice were deeply anesthetized with
pentobarbital and trans-cardially perfused with phosphate bufferd
saline (PBS), followed by phosphate buffered 4% paraformalde-
hyde. Brains were post-fixed in PFA over night and cryoprotected
in 30% sucrose/PBS for 2 days, then cut into 40 mm free-floating
sections using a Microm HM-560 cryostat (Thermo Scientific,
Waltham, MA) as described [31] and stored at 4uCi n
cryoprotection solution (25% glycerin, 25% ethylene glycol and
50% PBS) until use. After washing with PBS, permeabilization
with 0,2% TritonX-100 in PBS (PBS-Tx) and blocking in 4%
normal goat serum (NGS) in PBS-Tx, sections were incubated
overnight at 4uC with a combination of the following antibodies in
4% NGS in PBS-Tx: rabbit anti-aspa serum (1:1000); chicken
anti-b-Galactosidase (1:500, abcam); mouse anti-GFAP (1:1000,
Sigma-Aldrich, St. Luis, MO), respectively. For Iba-1 and b-
Galactosidase detection, antigen retrieval was performed prior to
permeabilization by rinsing free floating sections two times in PBS
followed by incubation in 10 mM sodium citrate buffer (pH 8.6) at
80uC for 30 min. Sections were allowed to cool down to room
temperature in the same solution followed by permeabilization
with PBS-Tx, blocking for 30 min in PBS-Tx 1% BSA (for anti-
Iba-1) or NGS (for b-Gal), and incubation with the primary
antibodies in blocking solution overnight at 4uC. Sections were
washed with PBS and incubated with appropriate Alexa-
conjugated secondary antibodies (1:1000, Invitrogen, Carlsbad,
CA) for 1–2 h at room temperature in 4% NGS in PBS-Tx,
mounted on slides and coverslipped with Mowiol (Calbiochem,
Darmstadt, Germany). For X-Gal histochemistry aspa
lacZ/+
animals were perfused in ice-cold 5% PFA, and tissues dissected
and postfixed for 1 h followed by embedding in Kaiser’s gelatine
(Merck, Darmstadt, Germany). Vibratome sections (60 mm;
Aspartoacylase-LacZ Knockin
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collected in PBS and incubated in X-gal solution (1.2 mg/ml X-
gal, 5 mM potassium ferrocyanide and 2 mM MgCl2 in PBS) for
4–12 h. After 3 washes in PBS sections were mounted and
coverslipped in Mowiol. For Nissl staining, sections were mounted
onto glass slides in PBS and air-dried, then stained for 10 s with
toluidine blue (0.1% in H2O). Slides were washed two times with
H2O, destained for 15 s in 70% ethanol / 0.001% acetic acid,
dehydrated in 100% ethanol and air-dried. After dipping in xylol,
sections were mounted with Histokit (Carl Roth, Karlsruhe,
Germany). Immunostaining was visualized using a Leica DMRA
inverted microscope (Leica Microsystems, Wetzlar, Germany) or a
Zeiss LSM 710 confocal microscope (Carl Zeiss MicroImaging,
Jena, Germany). Teased sciatic nerve preparations were done as
described [42]. Briefly, peripheral nerves were fixed by perfusion
or immersion in 4% PFA in 0,1 M phosphatebuffer, pH 7,4 for
30–60 min. After several washes with phosphate buffer, nerves
were teased on SuperFrostPlus slides in a 50 ml drop containing
PBS, and air-dried. Primary antibodies were anti ASPA and rat
anti MBP (1:1000; Abcam).
Electron microscopy
Animals were anesthetized with Avertin and perfused transcar-
dially with warm HBSS followed by fixing solution (4%
formaldehyde and 2.5% glutaraldehyde in phosphate buffer
containing 0.5% NaCl as described [43]. The CNS was dissected
and embedded in Epon (Serva) after postfixation with 2% OsO4
(Science Services, Munich, Germany) and dehydration with
ethanol and isopropanol and propylenoxid. Ultrathin sections
were cut using an Ultracut S ultramicrotome (Leica, Austria),
mounted on 100 mesh hexagonal copper EM grids (Plano,
Germany) and poststained with 4% aqueous uranyl acetate (SPI-
Supplies, USA) and lead citrate [44]. The sections were analyzed
in a LEO EM 912AB electron microscope (Zeiss, Oberkochen,
Germany), and pictures were taken with an on-axis 204862048
CCD camera (Proscan, Scheuring, Germany).
Immunoblotting
Animals weresacrificed at P60, organs dissected quickly and snap
frozen. Brains were homogenized under liquid nitrogen using
mortar and pestle. Aliquots were sonicated in tris buffered saline
(TBS) containing protease inhibitors (Complete, Roche Applied
Science, Mannheim, Germany) and protein concentration was
determined by the method of Bradford. 20 mg of protein were
mixed with 5x Laemmli reducing sample buffer, denatured for
5 min at 95uC (with exception of samples allocated for detection of
PLP), separated by SDS-PAGE and transferred onto nitrocellulose
membranes (Protran, Whatman; GE Healthcare, Dassel, Germany)
Membranes were probed with the following antibodies: rabbit anti-
aspa serum (1:1000), mouse anti-tubulin (1:400000, Sigma-Aldrich,
St. Luis, MO), mouse anti-CNPase (1:1000, Abcam, Cambridge,
UK), rat anti-MBP (1:1000; Abcam, Cambridge, UK), rat anti-PLP
aa3 (1:1000, gift of J. Trotter). Antibodies were detected by the
appropriate HRP-conjugated secondary antibodies (Dianova,
Hamburg, Germany) followed by ECL-detection.
Behavioural testing
Differences in innate anxiety and general locomotor behavior of
male and female aspa
lacZ/lacZ (males: n=8; females: n=7) and
aspa
+/+ (males: n=8; females: n=6) mice were assessed in the
open field test at P90. Animals were placed in the center of an
arena (40640640 cm) under bright light conditions (100 lux) and
monitored for 30 min. Total distance traveled and time spent in
the center area and in the periphery was analyzed using Smart
software (Panlab, Madrid, Spain). Using the same cohorts of
animals, motor learning was assessed using the rotarod test at P90.
Mice were familiarized with the apparatus (Ugo Basile, Comerio,
Italy) in two trials for two min at constant speed (4 rpm). In a series
of 3 trials per animal, the time that the mice remained on the
accelerating roller (4–40 rpm in 4 min) was scored. Between trials
the animals were allowed a 10 min period in their home cage. The
individual performances were averaged over 2 days.
1H MR spectroscopy
A male control mouse and an aspa-lacZ mouse (4 months) where
measured with
1H-Magnetic resonance spectroscopy on a 9.4T
Bruker BioSpec scanner (Bruker, Rheinstetten, Germany) equipped
with a cryogenic very low temperature, closed cycle cooled RF-coil.
Mice were anesthetized by a gas mixture of O2: 50% and air: 50%
with ca. 1.8% isoflurane. Respiration rate was monitored
throughout the experiment. Body temperature was maintained at
37uC by warm water circulation and verified by a rectal thermo
sensor. For voxel positioning and high resolution images of the
mouse brain were acquired with a T2-weighted RARE (rapid
acquisition with relaxation enhancement) (TE=11 ms, TR=2.5 s,
alpha =20u, two averages; Resolution 66*66*500 um
3). Spectra
wereacquired using aPRESS single voxelSequenceatanecho time
of TE=10 ms from a 12 ml( 2 6263m m
3) volume from the
thalamic region, with a repetition time of TR=4 s and 256
averages (NEX) resulting in a total acquisition time of 17 min per
spectrum (Fig. 7). Water suppression was done with the VAPOR
(Variable pule powers and optimized relaxation delays) method
interleaved with 6 outer-volume suppression slices. To ensure
optimal B0 homogeneity 1st and 2nd order shimming was
conducted with Fastmap over a volume of 56565m m
3 prior each
metabolite measurement resulting in a line width (fwhm) of the
unsuppressed water signal of 12 Hz or better. An additional one
shot unsuppressed waterline (RF-off) was acquired for each voxel,
which was used for eddy-current correction and water referencing.
Quantification was done according with LCModel by fitting the in
vivo spectra to phantom data of 16 metabolite solutions measured at
the samescanner. Macromolecule contributions werefitted through
simulated spectra at the relevant frequencies. Concentration values
were referenced to an unsuppressed water signal acquired from the
same voxel assuming a mean water-concentration of 46.1 M/l.
Statistics
All graphs and statistical analyses were done with GraphPad
Prism 4 software (La Jolla, CA). Student’s t-test was used for
statistical analysis. Myelin protein levels were analysed with One-
Way ANOVA followed by Bonferroni post-hoc test. Values are
presented as the mean 6 s.e.m and p ,0.05 was considered as
statistically significant.
Supporting Information
Figure S1 b-Galactosidase co-localizes with ASPA. Laser-
confocal immunodetection of b-Galactosidase (A) and ASPA (B) in
the thalamus of an aspa
lacZ/+ reporter mouse. (C) The nuclear
DAPI staining shows all cells in the tissue. (D) The merged picture
shows b-Galactosidase immunoreactivity in ASPA-positive oligo-
dendrocytes (arrowheads) but not in other cells (asterisks). Bar:
20 mm.
(TIF)
Figure S2 EM analysis of optic nerve. There are no obvious
histological differences between the control (A) and mutant (B)
optic nerve. Bar: 500 nm.
(TIF)
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absence of ASPA. Q-PCR analysis for detection of folh1 in total
RNA isolated from whole brains of aspa
+/+, aspa
lacZ/+ and aspa
lacZ/
lacZ littermates (P60, n=3) shows decreased folh1 mRNA in
homozygous mutants. aspa
+/+ expression levels were used as a
nominator.
(TIF)
Video S1 Gait abnormalities of aspa
lacZ/lacZ mice. Side-
by-side comparison of representative motor behaviour in an open
field. The split screen shows a male control mouse (left side in
horizontal split, top in vertical split) and an aspa
lacZ/lacZ littermate
(right side in horizontal split, bottom in vertical split) at two
months of age.
(WMV)
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